Biogen Inc. on Thursday tried to make the case for why two aborted studies of its experimental Alzheimer’s disease drug support its plan to seek approval from U.S. regulators, but skeptics said they remained unconvinced that the drug is effective. Biogen presented additional details from the studies at the Clinical Trials on Alzheimer’s Disease conference in San Diego, and said the new data showed that patients receiving the highest dose of the drug appeared to have slower declines in their cognitive abilities than patients...

Source: Wall Street Journal December 05, 2019 22:07 UTC